Actively Recruiting
A Phase III Clinical Trial to Evaluate Safety and Efficacy of Unilateral Intracochlear Injection of SENS-501 in Children With Severe to Profound Hearing Loss Due to Otoferlin Gene Mutations
Led by Sensorion · Updated on 2024-09-26
12
Participants Needed
2
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, and effectiveness of the gene therapy SENS-501 in children aged 6 to 31 months who have severe to profound hearing loss caused by mutations in the Otoferlin gene. This open-label Phase III study focuses on children with pre-lingual hearing loss due to these genetic mutations, aiming to better understand how this treatment works in this young population. The study involves administering SENS-501 directly into one ear using a special injection system. It includes a dose-escalation phase where children receive either a low or high dose, followed by a dose expansion phase where the dose recommended from earlier phases is given. The treatment is given as a single unilateral intracochlear injection, and the administration systems safety, performance, and usability are also evaluated. Participants will be followed for up to 5 years to monitor safety and tolerability and to assess hearing improvement using auditory brainstem response ABR and pure tone audiometry PTA. Additional evaluations include clinical checks of the administration system shortly after treatment. Throughout the study, children will undergo hearing tests and medical assessments to measure outcomes and track any side effects or complications from the treatment and procedure.
CONDITIONS
Brief Title
A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children (male or female) aged 6 to 31 months at the time of inclusion
- Severe to profound hearing loss confirmed by auditory brainstem response (ABR)
- Biallelic mutation in the Otoferlin gene
- Presence of Otoacoustic emissions (OAEs)
- Documented normal cochlea and internal auditory canals
- Intact vestibular function
You will not qualify if you...
- History of chronic, acute, or major disease or other reasons making participation unsafe or unsuitable
- Previous dosing in a gene therapy clinical trial
- Prior or current cochlear implant
- Any contraindication to surgery or anesthesia or history of prolonged ototoxic therapy (e.g., cisplatin, aminoglycosides over 2 weeks)
- Participation in another interventional clinical trial
- Any condition that may compromise safety, compliance, or interfere with treatment evaluation
- Anticipated noncompliance with study requirements
Research Team
L
Lionel HOVSEPIAN, MD
G
Géraldine HONNET, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here